BioNTech expands oncology pipeline amid various corporate insider stock sales

Various companies are reporting significant developments in clinical pipelines and insider stock transactions.

BioNTech SE is expanding its oncology portfolio beyond COVID-19 vaccines, with over 25 phase 2 and phase 3 cancer trials currently underway. The company aims to have 15 phase 3 trials active by the end of 2026, focusing on treatments like pumitamig for solid tumors including lung, breast, gastric, and kidney cancers.

In corporate finance news, several executives have executed stock sales. Rubrik CTO Arvind Nithrakashyap sold approximately $1.57 million in shares under a pre-arranged Rule 10b5-1 plan. SiTime Corporation insider Fariborz Assaderaghi sold $963,242.70 in stock. At SiBone, both insider Anshul Maheshwari and SVP Michael Pisetsky conducted share sales, with the latter noting the transactions were to cover tax withholding obligations related to equity award vesting.